Valuation: Abpro Corporation

Market Cap 13.45L 11.65L 10.86L 10L 18.85L 13Cr 19.07L 1.28Cr 50.08L 6.4Cr 50.51L 49.4L 21Cr P/E 2024
-2.41x
P/E 2025 -3.27x
Enterprise Value 14.25L 12.34L 11.5L 10.58L 19.98L 14Cr 20.2L 1.35Cr 53.06L 6.78Cr 53.52L 52.34L 22Cr EV / Sales 2024
497x
EV / Sales 2025 -
Free-Float
83.91%
Yield 2024 *
-
Yield 2025 -
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 13.45L
+0.90%+0.21%-0.74%+13.87% 4.8TCr
+1.98%+9.05%+413.94%+565.65% 4.11TCr
+3.44%-4.65%+28.34%+7.64% 3.76TCr
+1.40%+0.10%+6.61%+74.66% 3.59TCr
+2.42%+7.27%+14.90%+44.79% 2.99TCr
-0.16%-3.11% - - 1.61TCr
+2.20%+0.48%+34.71%+125.72% 1.61TCr
+1.25%+1.69%+4.72%+18.26% 1.38TCr
+4.25%-8.23%-1.49%-35.00% 1.21TCr
Average +1.71%-2.15%+62.62%+101.95% 2.78TCr
Weighted average by Cap. +1.80%-1.29%+82.52%+128.35%

Financials

2024 2025
Net sales 2L 2L 1L 1L 3L 1.74Cr 3L 17.36L 7L 87.07L 7L 7L 2.88Cr -
Net income -72.32L -62.64L -58.39L -53.7L -1.01Cr -69Cr -1.03Cr -6.86Cr -2.69Cr -34Cr -2.72Cr -2.66Cr -113.95Cr -28.92L -25.05L -23.35L -21.47L -40.54L -27Cr -40.99L -2.74Cr -1.08Cr -14Cr -1.09Cr -1.06Cr -46Cr
Net Debt 5L 4L 4L 4L 7L 4.55Cr 7L 45.35L 17.8L 2.27Cr 17.95L 17.56L 7.53Cr 80T 69.29T 64.59T 59.4T 1L 76.07L 1L 8L 3L 38.06L 3L 3L 1.26Cr
Logo Abpro Corporation
Abpro Holdings, Inc. is a biotechnology company. The Company is advancing a pipeline of next generation antibody therapies for human epidermal growth factor receptor 2 (HER2)+cancers, non-HER2+ gastric and liver cancer, and wet age-related macular degeneration (AMD) and diabetic macular edema (DME). These antibodies are developed using the Company’s proprietary DiversImmune platform. Its two lead product candidates, ABP-102 and ABP-201, feature its next generation tetravalent antibody format (TetraBi antibody format), which binds to two different targets with two distinct binding sites per target. ABP-102 is designed to redirect a patient’s immune system to fight cancer by engaging T cells through co-targeting HER2, and CD3, T-cell co-receptor. ABP-201 is designed to block blood vessel formation and normalize damaged vessels through co-targeting VEGF and ANG-2. It plans to develop ABP-201 to treat vascular disease of the eye, focusing on wet age-related macular degeneration (Wet AMD).
Employees
-